anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Control individuals will have no diagnosis of cardiac, vascular, metabolic, inflammatory or neurological disease, and have not been on any medication for such conditions in the past 12 months. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
Recent developments in near-infrared spectroscopy technology now permit rapid assessment of cerebral oxygenation (SctO2) using non-invasive probes. A high incidence cerebral desaturation events (CDE-defined as a decrease in SctO2 values below 20% of baseline measures or absolute SctO2 values ≤ 55 for ≥ 15 seconds) have been observed in previous investigation of patients undergoing shoulder surgery in BCP with hyperventilation. The investigators hypothesize that the incidence of CDE will be reduced in patients ventilated at normocapnic levels (end-tidal carbon dioxide values (ETCO2) of 40-42 mm Hg) when compared to subjects hyperventilated (ETCO2 of 30-32 mm Hg) in the operating room. Patients undergoing shoulder surgery in the BCP will be randomized to a hypocapnic group (ETCO2 of 30-32 mm Hg) or a normocapnic group (ETCO2 of 40-42 mm Hg). Cerebral oxygenation will be measured continuously throughout the procedure to assess perioperative SctO2 values and the incidence of CDE. The investigators previously observed an association between CDE in the operating room and postoperative nausea and vomiting. Therefore, the effect of ventilatory pattern and intraoperative SctO2 on clinical recovery will also be determined.
BACKGROUND: Coronavirus (COVID-19) is a virus that occurred in Wuhan, China, in December 2019 and has spread to several countries. Although interventions in water, sanitation, and hygiene (WASH) for COVID-19 are likely a pre-existing response to childhood diarrhea, evidence of the effects of COVID-19 preventative strategies on childhood diarrhea has been lacking. This study aimed to assess the implications of COVID-19 prevention for the occurrence of childhood diarrhea in rural communities of Ethiopia.
METHODS: A community-based cross-sectional study was conducted from 10 May 2020 to 30 July 2020 involving selected households in the Semen Bench district, Bench Sheko zone, southwestern Ethiopia. A single population proportion formula was used to obtain a total of 768 sample sizes. Data were collected from selected households using a simple random sampling technique. Epidata 3.1 was used to enter the data and then exported to Stata 14 for analysis. Descriptive statistics along with binary and multivariable logistic regression analyses were used to identify factors of COVID-19 knowledge and practices related to childhood diarrhea. The chi-squared test was used to check the association between COVID-19 prevention and childhood diarrhea reduction.
RESULTS: A total of 720 (93.75%) households participated in the study to achieve the study objectives. Approximately 55% of the participants had a good understanding of COVID-19 prevention, while only 48.5% had good COVID-19 prevention practices. The prevalence of childhood diarrhea was 19.3% which was more common among households with poor practices of COVID-19 prevention. The respondents with poor COVID-19 prevention knowledge were 42% (AOR = 0.58, 95% CI: 0.398, 0.847, P = 0.005) less likely to develop childhood diarrhea than those who had good COVID-19 prevention knowledge. Households with poor practices for COVID-19 prevention were 75.1% more likely to develop childhood diarrhea than those who had good preventive practices for COVID-19 prevention (AOR = 1.751, 95% CI: 1.193, 2.571, P = 0.004). The lower risk of childhood diarrhea is significantly related to good COVID-19 prevention practices. However, households with no formal education and a lack of WASH facilities have a higher likelihood of having childhood diarrhea in the household.
CONCLUSION: COVID-19 preventative strategies help reduce the prevalence of diarrhea in children. More research using prospective study designs and advanced statistical models is needed to better understand the implication of COVID-19 preventative efforts in reducing childhood diarrhea.
NEW MATERIAL:An anticancer antibiotic M143-37F11 expressed by the formula. USE:A medicine effective in Ehrlich solid cancer. The above-mentioned antibiotic has low toxicity and stronger anticancer activity and useful to remedy for human cancer. PREPARATION:An antibiotic M143-37F11 producing bacterium belonging to Streptoverticillium is cultured and anticancer antibiotic M143-37F11 is collected from the culture medium. As a nutritious source, a material usable as a nutri tious source of actinomyces, e.g. peptone, meat extract, corn, glucose or ammo nium nitrate which is put on the market is used. In the mass production of the aimed antibiotic, liquid culture is preferably used and culture temperature is normally 27-32 deg.C. The aimed antibiotic is obtained from the culture medium by extracting the antibiotic from cultured filtrate with a water miscible organic solvent such as ethyl acetate in weakly acidic conditions. The aimed antibiotic can be also purely collected by combining absorption chromatography, etc.
Subjects were treated once time. The subjects were lying in lateral decubitus. The common peroneal nerve was located with ultrasound (cross section) near to the peroneal head. After, an acupuncture needle (0,30mm x 30mm) was inserted in a long axis approach until the perineurium of the common peroneal nerve (in close proximity). The needle remains in this location during 200 seconds without any electrical current.
To compare recurrence rates after a 1-year follow-up period of healed neuroischemic diabetic foot ulcers after treatment with or without sucrose octasulfate impregnated dressing. A 1-year prospective study with two arms was conducted between April 2021 and April 2023 on 92 patients with healed neuroischemic diabetic foot ulcers. Patients were divided into two groups; the treatment group, that includes patients healed with a sucrose octasulfate-impregnated dressing, and the control group, which includes patients treated with other local treatments different from sucrose octasulfate-impregnated dressings. After healing, patients were prospectively followed up during 1-year and assessed monthly in the specialised outpatient clinics. The main outcome of the study was ulcer recurrence after wound healing within 1 year follow-up. Secondary outcomes were minor or major amputation and all causes of death. Fifty patients in the treatment group and 42 patients in the control group were included. Fourteen (28%) patients suffered from a reulceration event in the treatment group compared to 28 (66.7%) in the control group, p < 0.001. Time to recurrence in the treatment group was 10 (16.26-2.75) and 11.50 (30.75-5.25) weeks in the control group, p = 0.464. There were no observed differences in the minor amputation rates between the two groups: 15.2% (n = 7) in the treatment group and 7.1% (n = 3) in the control group (p = 0.362). Major amputations and death outcomes were exclusively observed in the treatment group. Specifically, four major amputations (8.7%) in the treatment group were complications arising from recurring events complicated by infection during the SARS-CoV-2 period. Seven patients died due to complications not related with local therapy. The relative risk of recurrence was 20.18 times higher in the control group compared with those treated with octasulfate dressing (p < 0.001). Treatment with sucrose octasulfate-impregnated dressings can decrease recurrence rates of neuroischaemic diabetic foot ulcers more effectively than neutral dressings. Besides, it may enhance the foot's clinical properties in patients with poor microcirculation, which could aid in preventing future recurrences.
PCT No. PCT/FR87/00262 Sec. 371 Date Feb. 3, 1988 Sec. 102(e) Date Feb. 3, 1988 PCT Filed Jul. 2, 1987 PCT Pub. No. WO88/00055 PCT Pub. Date Jan. 14, 1988.The subject of the invention is a water-soluble macromolecular conjugate of hemoglobin characterized in that it is constituted on the one hand, by hemoglobin, on the other, by a water-soluble polymer P containing polar groups, this macromolecular conjugate contains Z sites, bound to the polymer P and containing at least one negative charge carried for example by sulfate groups, the polymer P being bound to hemoglobin on the one hand, through the intermediary of at least one linkage established between at least one of the Z sites contained in the polymer and hemoglobin, and, on the other, through the intermediary of at least one covalent linkage established between the polymer and hemoglobin, or between at least one of the Z sites contained in the polymer and hemoglobin. The macromolecular conjugates according to the invention exhibit a lower affinity for oxygen than that of free hemoglobin.
PURPOSE: A composition containing courmarin compounds is provided to prevent and treat influenza viral infection diseases is provided to suppress neuraminidase activity. CONSTITUTION: A composition for preventing and treating influenza viral infection contains a compound of chemical formula 1 as an active ingredient. The compound of chemical formula 1 is isolated from Glycyrrhizae radix. The influenza virus is type A influenza virus, type B influenza virus, or type C influenza virus. The composition is a pharmaceutical, food, or non-medical product composition. A composition for suppressing neuraminidase activity contains the compound of chemical formula 1 as an active ingredient.
PURPOSE: An antibacterial composition containing chitosan is provided to ensure excellent antibacterial activity against gram positive bacteria, gram negative bacteria, yeast and fungi. CONSTITUTION: An antibacterial composition contains chitosan as an active ingredient. The molecular of chitosan is 12,000-25,000 Da. The antibacterial composition has antibacterial activity against Staphylococcus aureus, E.coli, Pseudomonas aeruginosa, Streptococcus mutans, Candida albicans or Aspergillus niger. The deacetylation of chitosan is 80-90%. A composition for preventing or treating diseases by microbial infection contains the antibacterial composition.
The present invention discloses a coronavirus subunit vaccine based on virus-like particles presenting coronavirus receptor binding domains. The present invention provides virus-like particles presenting specific proteins. The specific protein is RBD segment of S protein of SARS-CoV-2. The virus-like particle presenting the specific protein is obtained by modifying chikungunya virus-like particles as follows: the specific protein is inserted into the E2 protein of chikungunya virus. The insertion position may specifically be between amino acid residue 204 and amino acid residue 205 of the E2 protein of chikungunya virus. The virus-like particles can be used for preparing products; the application of the product is as follows: (e 1) as a novel coronavirus vaccine; (e 2) as a medicament for preventing and/or treating new coronatine pneumonia. The invention has important application and popularization value for SARS-CoV-2.
In advanced liver fibrosis (LF), macrophages maintain the inflammatory environment in the liver and accelerate LF deterioration by secreting proinflammatory cytokines. However, there is still no effective strategy to regulate macrophages because of the difficulty and complexity of macrophage inflammatory phenotypic modulation and the insufficient therapeutic efficacy caused by the extracellular matrix (ECM) barrier. Here, AC73 and siUSP1 dual drug-loaded lipid nanoparticle is designed to carry milk fat globule epidermal growth factor 8 (MFG-E8) (named MUA/Y) to effectively inhibit macrophage proinflammatory signals and degrade the ECM barrier. MFG-E8 is released in response to the high reactive oxygen species (ROS) environment in LF, transforming macrophages from a proinflammatory (M1) to an anti-inflammatory (M2) phenotype and inducing macrophages to phagocytose collagen. Collagen ablation increases AC73 and siUSP1 accumulation in hepatic stellate cells (HSCs) and inhibits HSCs overactivation. Interestingly, complete resolution of liver inflammation, significant collagen degradation, and HSCs deactivation are observed in methionine choline deficiency (MCD) and CCl4 models after tail vein injection of MUA/Y. Overall, this work reveals a macrophage-focused regulatory treatment strategy to eliminate LF progression at the source, providing a new perspective for the clinical treatment of advanced LF.
Extracorporeal membrane oxygen (ECMO) is a heart lung support device used for patients with severe and cardiac and respiratory failure and carries an increased risk of exposure to very high oxygen tensions. Hyperoxia (arterial oxygen \>100mmHg) can lead to the production of reactive oxygen species (ROS). Excess production of ROS and depletion of antioxidant compounds is referred to as oxidative stress and results in inflammation, tissue injury and cell death. The inter-relationship between the production of ROS and end organ dysfunction is complicated and remain unclear. A more detailed assessment of the timing of changes in markers of oxidative stress, inflammatory mediators and tissue injury is warranted to understand the processes and potentially identify therapeutic targets.

The BLENDER Trial is a multicentre trial in ECMO patients to determine whether a conservative oxygen strategy during ECMO reduces ICU length of stay and improves patient outcomes compared to a liberal oxygen strategy. Currently there have been no studies that look at the underlying pathophysiological changes that occur in patients on ECMO when subjected to different oxygen concentrations. As such The BLENDER study represents a unique opportunity to understand the mechanisms by which hyperoxia may cause tissue injury in patients receiving ECMO. This nested study seeks to elucidate whether exposure to hyperoxia during ECMO results in increased oxidative stress and whether this is correlated with increased risk of tissue injury and organ dysfunction. A better understanding of the mechanism of hyperoxia induced tissue injury may allow treatment to be optimised for patients exposed to hyperoxia as part of their treatment.
New procedure for obtaining 3-ethyl-5-methyl 2,6-dimethyl- 4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, in two stages. The obtaining of ethyl 2-(3- nitro)benzylideneacetoacetate from 3-nitrobenzaldehyde and ethyl acetoacetate in the presence of piperidine, glacial acetic acid and isopropanol, a second step in which the previous product is treated with methyl 3- aminocrotonate in the presence of activated alumina to give the title product. Advantages which are obtained by this procedure relative to the prior art: a) Processes carried out under rapid, smooth and simple conditions, giving products of high quality. b) The last step is carried out in a solid phase, avoiding traces of symmetrical dihydropyridines. c) Obtaining of the dihydropyridine without a solvent, minimum production of contaminating effluent. d) Use of recyclable basic or acid catalysts. e) Low cost in the processes, minimization of reagents and residues. f) Low environmental impact. <IMAGE>
INTRODUCTION: Zenker's diverticulum (ZD) is a false pulsion diverticulum of the cervical esophagus. It is typically found in older adults and manifests with dysphagia. The purpose of this study is to describe our experience with Per-oral endoscopic myotomy for Zenker's (Z-POEM) and intraoperative impedance planimetry (FLIP).
METHODS: We performed a single institution retrospective review of patients undergoing Z-POEM in a prospective database between 2014 and 2022. Upper esophageal sphincter (UES) distensibility index (DI, mm2/mmHg) was measured by FLIP before and after myotomy. The primary outcome was clinical success. Secondary outcomes included technical failure, adverse events, and quality of life as assessed by the gastroesophageal health-related quality of life (GERD-HRQL), reflux severity index (RSI), and dysphagia score. A statistical analysis of DI was done with the paired t-test (p < 0.05).
RESULTS: Fifty-four patients underwent Z-POEM, with FLIP measurements available in 30 cases. We achieved technical success and clinical success in 54/54 (100%) patients and 46/54 patients (85%), respectively. Three patients (6%) experienced contained leaks. Three patients were readmitted: one for aforementioned contained leak, one for dysphagia, and one post-operative pneumonia. Three patients with residual dysphagia underwent additional endoscopic procedures, all of whom had diverticula > 4 cm. Following myotomy, mean DI increased by 2.0 ± 1.7 mm2/mmHg (p < 0.001). In those with good clinical success, change in DI averaged + 1.6 ± 1.1 mm2/mmHg. Significant improvement was found in RSI and GERD-HRQL scores, but not dysphagia score.
CONCLUSION: Z-POEM is a safe and feasible for treatment of ZD. We saw zero cases of intraoperative abandonment. We propose that large diverticula (> 4 cm) are a risk factor for poor outcomes and may require additional endoscopic procedures. An improvement in DI is expected after myotomy, however, the ideal range is still not known.
The present invention relates to a lauromacrogol injection and a preparation method thereof. Aiming at the current rapid increase of the morbidity of massive hemorrhage of gastrointestinal tracts, a plurality of hospitals currently establish an introscope treatment center one after another and carry on the treatment of minimally invasive surgery. Lauromacrogol injections at abroad are used for emergent hemostasis of endoscope hemorrhage of varicose veins of oesophagi and the treatment of hardening of varicose veins, and however, the existing lauromacrogol injections as medicines at abroad are not reported detailedly. The lauromacrogol injection of the present invention has the formula that 100 ml of injection water contains 1g of lauromacrogol and 5 ml of ethanol. The present invention adopts the ethanol on the basis that the main medicine is easily dissolved in the ethanol, and the product quality can be effectively ensured; simultaneously, the ethanol has a slight anesthetic function, a patient feels no pain in the process of injection and is quiet, and the patient is easy to treat; simultaneously, the lauromacrogol injection has the advantages of less number of times for injection, small viscosity and easy injection by push. A thin needle head can be used, no pain is generated in the process of injection, and small side effect is realized after operation. Complications rarely occur, and no report of death and anaphylactic reaction is made.
Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of lower socioeconomic status (SES) and will be Caucasian/White.
Hypersensitivity to any component of this medication. Lescol® (fluvastatin sodium) and Lescol® XL (fluvastatin sodium) are contraindicated in patients with active liver disease or unexplained, persistent elevations in serum transaminases (see WARNINGS).

Pregnancy and Lactation

Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Cholesterol and other products of cholesterol biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). Since HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Therefore, HMG-CoA reductase inhibitors are contraindicated during pregnancy and in nursing mothers. Fluvastatin sodium should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the patient becomes pregnant while taking this class of drug, therapy should be discontinued and the patient apprised of the potential hazard to the fetus.
LncRNAs are reported to participate in multiple biological and pathological processes, including renal fibrosis due to obstructive nephropathy. However, the function and mechanisms of each lncRNA in this context differ. In this study, we created a fibrosis model in vitro using TGF-β1 treatment and in vivo through unilateral ureteral obstruction. We demonstrated that lncRNA6524 expression increased in both models, as confirmed by qPCR. Additionally, we discovered that lncRNA6524 mediates the TGF-β1-induced accumulation of extracellular matrix (ECM) proteins in BUMPT cells. We investigated the mechanism using dual luciferase reporter assays, immunofluorescence, and qPCR. Our results indicate that lncRNA6524 acts as a sponge for miR-92a-2-5p, promoting renal fibrosis by upregulating the Dvl1/Wnt/β-catenin signaling pathway. In summary, our findings demonstrate a linear regulatory relationship among lncRNA6524, miR-92a-2-5p, and the Dvl1/Wnt/β-catenin axis in renal epithelial cells during kidney obstruction. This highlights a new potential target for treating obstruction-related renal fibrosis.
HDR syndrome is a rare disease characterized by hypoparathyroidism, deafness, and renal dysplasia. An autosomal dominant disease caused by heterozygous pathogenic GATA3 variants, the penetrance of each associated condition is variable. Literature reviews have provided some answers, but many questions remain, in particular what the relationship is between genotype and phenotype. The current study examines 28 patients with HDR syndrome combined with an exhaustive review of the literature. Some conditions such as hearing loss are almost always present, while others described as rare initially, do not seem to be so rare after all (genital malformations and basal ganglia calcifications). By modeling pathogenic GATA3 variants found in HDR syndrome, we found that missense variations appear to always be located in the same area (close to the two Zinc Finger domain). We describe new pathogenic GATA3 variants, of which some seem to always be associated with certain conditions. Many audiograms were studied to establish a typical audiometric profile associated with a phenotype in HDR. As mentioned in the literature, hearing function should always be assessed as early as possible and follow up of patients with HDR syndrome should include monitoring of parathyroid function and vesicoureteral reflux in order to prevent complications.